New stroke drug shows promise in recovery trial

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female. * ≥18 years old or legal age as per country requirement * Diagnosed with acute ischemic stroke with compatible brain imaging findings between 2 days to 10 days (inclusive) prior to inclusion. * NIHSS total score of 8 to 18 (inclusive) at the time of inclusion with a combined score of at least 3 on the NIHSS motor items 5A or 5B and/or 6A or 6B. * A candidate for active rehabilitation in the opinion of the treating physician. * Able to comply with the requirements of the protocol and provide written informed consent by patient or legal representative before any study-specific procedure is performed. Exclusion Criteria: * Pre-stroke modified Rankin score of \>1. * Contraindication to any of the study procedures. * Patients who became medically unstable within 24 hours after intravenous or endovascular thrombolysis or thrombectomy. * Intake of any herbal or traditional medicine within the past 30 days. * Participation in another investigational drug or device trial within the past 30 days. * Intake of warfarin in the past one week or expected to be on warfarin while in the study. * Women who are pregnant or wish to continue breastfeeding while in the study. Women of child-bearing potential may be included if they agree to strict abstinence or use of effective contraception, except systemically acting hormonal contraceptives. Hormone replacement therapy in menopausal/post-menopausal or surgically sterilized women is also not allowed while in the study. * Any known food allergy or hypersensitivity to Astragalus membranaceus, Ligusticum chuanxiong, Polygala tenuifolia, Angelica sinensis, or members of the Fabaceae/Leguminosae family (e.g., legume, pea, bean), Polygalaceae family (e.g., milkwort, snakeroot), Apiaceae/Umbelliferae family (e.g., anise, caraway, carrot, celery, dill, parsley, parsnip), or Quillaja bark (soapbark). * Evidence of other significant non-ischemic brain lesion which could affect long-term function or disability. * Evidence of advanced medical condition that would affect study assessment and follow-up, such as cancer, renal failure, liver cirrhosis, severe dementia, or psychosis. * Any other medical or psychiatric or cognitive condition which, in the study investigator's opinion, may jeopardize the patient by his/her participation in this study, may hamper his/her ability to complete procedures required in the study, affect study assessment and follow-up, or affect the validity of the study results.